The recent approval in the US and Europe of imatinib (Gleevac™) for patients with bcr/abl-positive chronic myelogenous leukemia and the considerable public interest in new anticancer drugs that take advantage of specific genetic defects that render the malignant cells more likely to respond to specific treatment are driving a new era of integrated diagnostics and therapeutics.
American Journal of Cancer – Springer Journals
Published: Aug 10, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.